FindTrial
Sign In

Efficacy and tollerability of thiamphenicol glycinate acetylcysteinate, given in sequential therapy sistematic and aerosol or by aerosol in the treatment of hight respiratory tract acute infection and/or subacute/recurring clinical study, multicentre, randomized, controlled vs standard therapy

Efficacy and tollerability of thiamphenicol glycinate acetylcysteinate, given in sequential therapy sistematic and aerosol or by aerosol in the treatment of hight respiratory tract acute infection and/or subacute/recurring clinical study, multicentre, randomized, controlled vs standard therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001901-81-IT
Enrollment
912
Registered
2007-03-15
Start date
2004-07-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

terapia sequenziale sistemica ed aerosol delle infezioni acute e/o subacute/ricorrenti delle alte vie respiratorie MedDRA version: 6.1 Level: HLGT Classification code 10004018

Interventions

Trade Name: FLUIMUCIL ANT.IN.TOP*AD 3F 500 Pharmaceutical Form: Nebuliser solution INN or Proposed INN: Thiamphenicol Concentration unit: mg milligram(s) Concentration type: equal Concentration numb

Sponsors

AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026